Survival of breast cancer patients according to changes in expression of selected markers between primary tumor and lymph node metastases

Biomarkers in Medicine

Volumn 10, Issue 3, 2016, Pages 219-228

  Adamczyk, Agnieszka ^a   Niemiec, Joanna ^a   Ambicka, Aleksandra ^a   Mucha Małecka, Anna ^a   Rys̈, Janusz ^a   Mitus̈, Jerzy ^a   Wysocki, Wojciech M ^a   Cichocka, Anna ^a   Jakubowicz, Jerzy ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

breast carcinoma; changes in proteins expression; lymph node metastases; primary tumor

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD24 ANTIGEN; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; HERMES ANTIGEN; KI 67 ANTIGEN; P CADHERIN; PROGESTERONE RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN EXPRESSION; VERY ELDERLY; BREAST TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SENTINEL LYMPH NODE; SURVIVAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; PROPORTIONAL HAZARDS MODELS; SENTINEL LYMPH NODE; SURVIVAL ANALYSIS;

EID: 84959515208     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.123     Document Type: Article

References (36)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Gao D, Li S. Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases. Cancer Microenviron. 6, 213-230 (2013).
3. Nguyen DX, Massagué J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 8, 341-352 (2007).
4. Kraljevic Pavelic S, Sedic M, Bosnjak H, Spaventi S, Pavelic K. Metastasis: new perspectives on an old problem. Mol. Cancer 10, 22 (2011).
5. Falck AK, Fernö M, Bendahl PO, Rydé L. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer ? World J. Surg. 34, 1434-1441 (2010).
6. Niikura N, Liu J, Hayashi N et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol. 30, 593-599 (2012).
7. Bogina G, Bortesi L, Marconi M et al. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss. Virchows Arch. 459, 1-10 (2011).
8. Heitz F, Barinoff J, du Bois O et al. Differences in the receptor status between primary and recurrent breast cancerthe frequency of and the reasons for discordance. Oncology 84, 319-325 (2013).
9. Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J. Surg. Oncol. 9, 131 (2011).
10. Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int. J. Cancer 122, 999-1004 (2008).
11. D'Andrea MR, Limiti MR, Bari M et al. Correlation between genetic and biological aspects in primary nonmetastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res. Treat. 101, 279-284 (2007).
12. Dong Y, Bi LR, Xu N et al. The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis. Pathol. Res. Pract. 209, 555-561 (2013).
13. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. Eur. J. Surg. Oncol. 28, 383-387 (2002).
14. Adamczyk A, Niemiec J, Ambicka A et al. Expression of ER/PR/HER2, basal markers and adhesion molecules in primary breast cancer and in lymph nodes metastases: A comparative immunohistochemical analysis. Pol. J. Pathol. 63, 228-234 (2012).
15. Cho EY, Han JJ, Choi YL, Kim KM, Oh YL. Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study. J. Korean Med. Sci. 23, 1053-1061 (2008).
16. Yoshioka T, Umekita Y, Ohi Y et al. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: A long-term follow-up study. Histopathology 58, 608-616 (2011).
17. Dikicioglu E, Barutca S, Meydan N, Meteoglu I. Biological characteristics of breast cancer at the primary tumour and the involved lymph nodes. Int. J. Clin. Pract. 59, 1039-1044 (2005).
18. Cummings MC, Simpson PT, Reid LE et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J. Pathol. 232, 23-31 (2014).
19. Gojis O, Kubecova M, Rosina J et al. Expression of selected proteins in breast cancer brain metastases. Folia Histochem. Cytobiol. 51, 213-218 (2013).
20. Grupka NL, Lear-Kaul KC, Kleinschmidt-DeMasters BK, Singh M. Epidermal growth factor receptor status in breast cancer metastases to the central nervous system. Comparison with HER-2/neu status. Arch. Pathol. Lab. Med. 128, 974-979 (2004).
21. Guler G, Balci S, Costinean S et al. Stem cell-related markers in primary breast cancers and associated metastatic lesions. Mod. Pathol. 25, 949-955 (2012).
22. Hoefnagel LD, van de Vijver MJ, van Slooten HJ et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res. 12, R75 (2010).
23. Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5 in early and late relapsing breast cancer-reduced CK5 expression in metastases. Breast Cancer 7, 23-34 (2013).
24. Sun L, Yu DH, Sun SY, Zhuo SC, Cao SS, Wei L. Expressions of ER, PR, HER-2, COX-2, and VEGF in primary and relapsed/metastatic breast cancers. Cell Biochem. Biophys. 68, 511-516 (2014).
25. Nogami T, Shien T, Tanaka T et al. The discordance between primary breast cancer lesions and pulmonary metastatic lesions in expression of aldehyde dehydrogenase 1-positive cancer cells. Breast Cancer 21(6), 698-702 (2014).
26. Böcker W, Moll R, Poremba C et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: A new cell biological concept. Lab. Invest. 82(6), 737-746 (2002).
27. Pituch-Noworolska A, Drabik G, Szatanek R et al. Immunophenotype of isolated tumour cells in the blood, bone marrow and lymph nodes of patients with gastric cancer. Pol. J. Pathol. 58(2), 93-97 (2007).
28. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007).
29. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20, 1319-1329 (2009).
30. Dowsett M, Nielsen TO, A'Hern R et al. International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J. Natl Cancer Inst. 103(22), 1656-1664 (2011).
31. Takes RP, Baatenburg de Jong RJ, Wijffels K et al. Expression of genetic markers in lymph nodemetastases compared with their primary tumours in head and neck cancer. J. Pathol. 194, 298-302 (2001).
32. Ellsworth RE, Seebach J, Field LA et al. A gene expression signature that defines breast cancer metastases. Clin. Exp. Metastasis. 26, 205-213 (2009).
33. Moelans CB, van der Groep P, Hoefnagel LD et al. Genomic evolution from primary breast carcinoma to distant metastasis: few copy number changes of breast cancer related genes. Cancer Lett. 344, 138-146 (2014).
34. Popławski AB, Jankowski M, Erickson SW et al. Frequent genetic differences between matched primary and metastatic breast cancer provide an approach to identification of biomarkers for disease progression. Eur. J. Hum. Genet. 18, 560-568 (2010).
35. Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van't Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl Acad. Sci. USA 100, 15901-15905 (2003).
36. Weigelt B, Wessels LF, Bosma AJ et al. No common denominator for breast cancer lymph node metastasis. Br. J. Cancer 93, 924-932 (2005).